Glenmark Pharmaceuticals Recalls 1,200 Bottles Of Hypertension Drug In US

New Delhi : Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

The New Jersey-based arm of the drug firm is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, Batch # 19224744 as per the latest Enforcement Report of the US health regulator.

The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA said.

The firm is recalling the affected bottles due to it being “Subpotent”, it noted.

Subpotent means ‘Out of Specification for Assay Test at the 3-month time point.’

Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, it added.

As per the USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Related Posts

Three arrested after liquor bottles found at pharma firm

Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

Anton Paar India hosted the first day of NEXUS 2026 at Ramada by Wyndham, Navi Mumbai, bringing together leading experts, scientists, researchers and industry professionals from the pharmaceutical sector for…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Three arrested after liquor bottles found at pharma firm

Three arrested after liquor bottles found at pharma firm

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two

Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two